




Instance: composition-en-2c250051417033f9ca5609b812b532b2
InstanceOf: CompositionUvEpi
Title: "Composition for livtencity Package Leaflet"
Description:  "Composition for livtencity Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1ca97300ba5836420ff4607613719f22)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - livtencity"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What LIVTENCITY is and what it is used for</li>
<li>What you need to know before you take LIVTENCITY</li>
<li>How to take LIVTENCITY</li>
<li>Possible side effects</li>
<li>How to store LIVTENCITY</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What livtencity is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What livtencity is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>LIVTENCITY is an antiviral medicine that contains the active substance maribavir.
It is a medicine used to treat adults who have had an organ or bone marrow transplant and developed a 
CMV ( cytomegalovirus ) infection that did not go away or came back again after taking another 
antiviral medicine.
CMV is a virus that a lot of people have without symptoms and normally just stays in the body
without causing any harm. However, if your immune system is weakened after you get an organ or 
bone marrow transplant, you may be at higher risk of becoming ill from CMV.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take livtencity"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take livtencity"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take LIVTENCITY</p>
<p>if you are allergic to the active substance or any of the other ingredients of this medicine (listed in 
section 6).</p>
<p>if you take either of these medicines:<em> ganciclovir (used to manage CMV infection)</em> valganciclovir (used to manage CMV infection)
You should not be given LIVTENCITY if any of the above apply to you. If you are not sure, talk to 
your doctor, pharmacist or nurse before you are given LIVTENCITY.
Warnings and precautions 
Talk to your doctor or pharmacist before taking LIVTENCITY if you are already being treated with 
cyclosporine, tacrolimus, sirolimus or everolimus (medicines to prevent transplant rejection). 
Additional blood tests may be needed to check the blood levels of these medicines. High levels of 
these medicines may cause serious side effects.
Children and adolescents
LIVTENCITY is not for use in children and adolescents under 18 years old. This is because 
LIVTENCITY has not been tested in this age group.
Other medicines and LIVTENCITY
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. This is because LIVTENCITY may affect the way other medicines work, and other
medicines may affect how LIVTENCITY works. Your doctor or pharmacist will tell you if it is safe to 
take LIVTENCITY with other medicines.
There are some medicines you must not take with LIVTENCITY. See list under  Do not take
LIVTENCITY .
Also tell your doctor if you are taking any of the following medicines. This is because your doctor 
may have to change your medicines or change the dose of your medicines:</p>
<p>rifabutin, rifampicin   for tuberculosis (TB) or related infections</p>
<p>St. John's wort (Hypericum perforatum)   a herbal medicine for depression and sleep problems</p>
<p>statins, such as atorvastatin, fluvastatin, rosuvastatin, simvastatin, pravastatin, pitavastatin   for 
high cholesterol</p>
<p>carbamazepine, phenobarbital, phenytoin   usually for fits or seizures (epilepsy)</p>
<p>efavirenz, etravirine, nevirapine - used to treat HIV infection</p>
<p>antacid (aluminium and magnesium hydroxide oral suspension)   for heartburn or indigestion 
due to excess stomach acid</p>
<p>famotidine   for heartburn or indigestion due to excess stomach acid</p>
<p>digoxin   heart medicine</p>
<p>clarithromycin  antibiotic</p>
<p>ketoconazole and voriconazole   for fungal infections</p>
<p>diltiazem   heart medicine</p>
<p>dextromethorphan   cough medicine</p>
<p>warfarin   anticoagulant</p>
<p>oral contraceptive steroids   for birth control</p>
<p>midazolam   used as a sedative
You can ask your doctor, pharmacist or nurse for a list of medicines that may interact with 
LIVTENCITY.
Pregnancy
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for
advice before taking this medicine. LIVTENCITY is not recommended in pregnancy. This is because 
it has not been studied in pregnancy and it is not known if LIVTENCITY will harm your baby while 
you are pregnant.
Breast-feeding
If you are breast-feeding or are planning to breast-feed, tell your doctor before taking this medicine.
Breast-feeding is not recommended while taking LIVTENCITY. This is because it is not known if
LIVTENCITY can pass into your breast milk or if this would affect your baby.
Driving and using machines
LIVTENCITY has no influence on your ability to drive or to use machines.
LIVTENCITY contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 
 sodium-free .</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take livtencity"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take livtencity"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your 
doctor, pharmacist or nurse if you are not sure. 
The recommended dose is 400 mg twice a day. That means you take two tablets of LIVTENCITY 
200 mg in the morning, and another two tablets of 200 mg in the evening. You can take this medicine 
with or without food, as a whole tablet or a crushed tablet.
If you take more LIVTENCITY than you should
If you take too much LIVTENCITY, tell your doctor straight away.
If you forget to take LIVTENCITY
If you miss a dose, and there are less than 3 hours left until your next regular dose is due, then skip the 
missed dose and go back to your regular schedule. Do not take a double dose to make up for a 
forgotten dose.
If you stop taking LIVTENCITY
Even if you feel better, do not stop taking LIVTENCITY without talking to your doctor. Taking 
LIVTENCITY as recommended should give you the best chance of clearing CMV infection and/or 
disease.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor, pharmacist or nurse if you notice any of the following side effects:
Very common (may affect more than 1 in 10 people):</p>
<p>changes in the way things taste</p>
<p>feeling sick (nausea)</p>
<p>diarrhoea</p>
<p>being sick (vomiting)</p>
<p>tiredness (fatigue)
Common (may affect up to 1 in 10 people):</p>
<p>Increased blood levels of medicines used to prevent transplant rejections </p>
<p>stomach (abdominal) pain</p>
<p>loss of appetite</p>
<p>headache</p>
<p>weight loss
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store livtencity"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store livtencity"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date that is stated on the carton and bottle label after EXP. 
The expiry date refers to the last day of that month.
Do not store above 30  C.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help to protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>What LIVTENCITY contains</h2>
<h2>The active substance is maribavir. Each film-coated tablet contains 200 mg maribavir</h2>
<h2>The other ingredients (excipients) are</h2>
<h2>Tablet core:</h2>
<p>Microcrystalline cellulose (E460(i)), Sodium starch glycolate (see section 2), Magnesium stearate 
(E470b)
-
Film coating:
-
Polyvinyl alcohol (E1203), Macrogol (i.e. polyethylene glycol) (E1521), Titanium dioxide (E171), 
Talc (E553b), Brilliant blue FCF aluminum lake (EU) (E133)
What LIVTENCITY looks like and contents of the pack
LIVTENCITY 200 mg film coated tablets are blue, oval shaped convex debossed with  SHP  on one 
side and  620  on the other side.
The tablets are packaged in high-density polyethylene (HDPE) bottles with child resistant cap contains 
either 28, 56 or 112 (2 bottles of 56) film-coated tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza
50-58 Baggot Street Lower
Dublin 2
D02 HWIreland
Manufacturer
Takeda Ireland Limited
Bray Business Park
Kilruddery
Co. Wicklow
Ireland
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:
Belgi /Belgique/Belgien
Takeda Belgium NV
T l/Tel: +32 2 464 06 medinfoEMEA@takeda.com
Lietuva
Takeda, UAB
Tel: +370 521 09 medinfoEMEA@takeda.com</p>
<p>.: +359 2 958 27 medinfoEMEA@takeda.com 
Luxembourg/Luxemburg
Takeda Belgium NV
T l/Tel: +32 2 464 06 medinfoEMEA@takeda.com
 esk  republika
Takeda Pharmaceuticals Czech Republic s.r.o.
Tel: + 420 234 722 medinfoEMEA@takeda.com
Magyarorsz g
Takeda Pharma Kft.
Tel.: +36 1 270 7medinfoEMEA@takeda.com
Danmark
Takeda Pharma A/S
Tlf: +45 46 77 10 medinfoEMEA@takeda.com
Malta
 akeda HELLAS S.A.
Tel: +30 210 6387medinfoEMEA@takeda.com
Deutschland
Takeda GmbH
Tel: +49 (0)800 825 3medinfoEMEA@takeda.com
Nederland
Takeda Nederland B.V.
Tel: +31 20 203 5medinfoEMEA@takeda.com
Eesti
Takeda Pharma AS
Tel: +372 6177 medinfoEMEA@takeda.com
Norge
Takeda AS
Tlf: +47 800 800 medinfoEMEA@takeda.com</p>
<p>akeda    . .
T : +30 210 6387medinfoEMEA@takeda.com
 sterreich
Takeda Pharma Ges.m.b.H. 
Tel: +43 (0) 800-20 80 medinfoEMEA@takeda.com
Espa a
Takeda Farmac utica Espa a S.A.
Tel: +34 917 90 42 medinfoEMEA@takeda.com
Polska
Takeda Pharma Sp. z o.o.
Tel.: +48223062medinfoEMEA@takeda.com
France
Takeda France SAS
T l: + 33 1 40 67 33 medinfoEMEA@takeda.com
Portugal
Takeda Farmac uticos Portugal, Lda.
Tel: + 351 21 120 1medinfoEMEA@takeda.com
Hrvatska
Takeda Pharmaceuticals Croatia d.o.o.
Tel: +385 1 377 88 medinfoEMEA@takeda.com
Rom nia
Takeda Pharmaceuticals SRL
Tel: +40 21 335 03 medinfoEMEA@takeda.com
Ireland
Takeda Products Ireland Ltd
Tel: 1800 937 medinfoEMEA@takeda.com
Slovenija
Takeda Pharmaceuticals farmacevtska dru ba d.o.o.
Tel: + 386 (0) 59 082 medinfoEMEA@takeda.com
 sland
Vistor hf.
S mi: +354 535 7medinfoEMEA@takeda.com
Slovensk  republika
Takeda Pharmaceuticals Slovakia s.r.o.
Tel: +421 (2) 20 602 medinfoEMEA@takeda.com
Italia
Takeda Italia S.p.A.
Tel: +39 06 502medinfoEMEA@takeda.com
Suomi/Finland
Takeda Oy
Puh/Tel: 0800 774 medinfoEMEA@takeda.com</p>
<p>akeda    . .
 .: +30 210 6387medinfoEMEA@takeda.com
Sverige
Takeda Pharma AB
Tel: 020 795 medinfoEMEA@takeda.com
Latvija
Takeda Latvia SIA
Tel: +371 67840medinfoEMEA@takeda.com
United Kingdom (Northern Ireland)
Takeda UK Ltd
Tel: +44 (0) 2830 640 medinfoEMEA@takeda.com
This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-2c250051417033f9ca5609b812b532b2
InstanceOf: CompositionUvEpi
Title: "Composition for livtencity Package Leaflet"
Description:  "Composition for livtencity Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1ca97300ba5836420ff4607613719f22)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - livtencity"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du begynder at tage LIVTENCITY </li>
<li>Sådan skal du tage LIVTENCITY </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What livtencity is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What livtencity is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>LIVTENCITY er et antiviralt lægemiddel, der indeholder det aktive stof maribavir. </p>
<p>Lægemidlet anvendes til behandling af voksne, som har modtaget en organ- eller 
knoglemarvstransplantation og derefter udviklet en CMV(cytomegalovirus)-infektion, som ikke er 
forsvundet eller er kommet tilbage, efter at være behandlet med et andet antiviralt lægemiddel. </p>
<p>CMV er en virus, som mange mennesker har uden symptomer, og normalt bliver den bare i kroppen 
uden at forårsage skade. Men hvis dit immunsystem er svækket, efter du har fået en organ- eller 
knoglemarvstransplantation, kan du have større risiko for at blive syg af CMV. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take livtencity"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take livtencity"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke LIVTENCITY 
 
hvis du er allergisk over for det aktive stof eller et af de øvrige indholdsstoffer i dette lægemiddel 
(angivet i punkt 6). 
 
hvis du tager et af disse lægemidler: * ganciclovir (anvendes til at behandle CMV-infektion) * valganciclovir (anvendes til at behandle CMV-infektion) </p>
<p>Hvis noget af dette gælder for dig, må du ikke få LIVTENCITY. Kontakt lægen, apotekspersonalet 
eller sygeplejersken, før du får LIVTENCITY, hvis du ikke er sikker. </p>
<p>Advarsler og forsigtighedsregler<br />
Kontakt lægen eller apotekspersonalet, før du tager LIVTENCITY, hvis du allerede bliver behandlet 
med ciclosporin, tacrolimus, sirolimus eller everolimus (lægemidler til forebyggelse af 
transplantatafstødning). Der kan være behov for yderligere blodprøver for at tjekke niveauet af disse 
lægemidler i blodet. Høje niveauer af disse lægemidler kan give alvorlige bivirkninger. </p>
<p>Børn og unge 
LIVTENCITY er ikke beregnet til børn og unge under 18 år. Det skyldes, at LIVTENCITY ikke er 
blevet undersøgt i denne aldersgruppe. </p>
<p>Brug af anden medicin sammen med LIVTENCITY 
Fortæl lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget anden medicin 
eller planlægger at tage anden medicin. Dette er fordi LIVTENCITY kan påvirke virkningen af anden 
medicin, og anden medicin kan påvirke LIVTENCITYs virkning. Lægen eller apotekspersonalet kan 
fortælle dig, om det er sikkert at tage LIVTENCITY sammen med anden medicin. </p>
<p>Der er visse lægemidler, som du ikke må tage sammen med LIVTENCITY. Se listen under "Tag ikke 
LIVTENCITY". </p>
<p>Fortæl det også til lægen, hvis du tager nogen af følgende lægemidler. Det kan være nødvendigt, at 
lægen ændrer dine lægemidler eller ændrer din lægemiddeldosis: </p>
<p> 
rifabutin, rifampicin - mod tuberkulose (TB) eller relaterede infektioner 
 
Perikon (Hypericum perforatum) - et naturlægemiddel mod depression og søvnproblemer 
 
statiner såsom atorvastatin, fluvastatin, rosuvastatin, simvastatin, pravastatin, pitavastatin - mod 
forhøjet kolesterol 
 
carbamazepin, phenobarbital, phenytoin - bruges normalt mod krampeanfald (epilepsi) 
 
efavirenz, etravirin, nevirapin - anvendes til at behandle hiv-infektion 
 
antacidum (aluminium- og magnesiumhydroxid, oral suspension) - mod halsbrand eller 
fordøjelsesproblemer på grund af for meget mavesyre 
 
famotidin - mod halsbrand eller fordøjelsesproblemer på grund af for meget mavesyre 
 
digoxin - hjertemedicin 
 
clarithromycin - antibiotikum 
 
ketoconazol og voriconazol - mod svampeinfektion 
 
diltiazem - hjertemedicin 
 
dextromethorphan - hostemedicin 
 
warfarin - blodfortyndende middel 
 
p-piller - prævention 
 
midazolam - anvendes som beroligende middel </p>
<p>Du kan bede lægen, apotekspersonalet eller sygeplejersken om en liste over lægemidler, der kan 
påvirke/blive påvirket af LIVTENCITY. </p>
<p>Graviditet 
Hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge 
din læge til råds, før du tager dette lægemiddel. LIVTENCITY frarådes under graviditet. Det skyldes, 
at i LIVTENCITY ikke er undersøgt hos gravide, og det vides ikke, om det kan skade dit barn, mens 
du er gravid. </p>
<p>Amning 
Hvis du ammer eller planlægger at amme, skal du kontakte lægen, før du tager dette lægemiddel. Det 
frarådes at amme, mens du tager LIVTENCITY. Det skyldes, at det ikke vides, om LIVTENCITY kan 
udskilles i modermælk, eller om det kan påvirke dit barn. </p>
<p>Trafik- og arbejdssikkerhed 
LIVTENCITY påvirker ikke evnen til at føre motorkøretøj og betjene maskiner. </p>
<p>LIVTENCITY indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take livtencity"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take livtencity"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens, apotekspersonalets eller sygeplejerskens anvisning. Er du i 
tvivl, så spørg lægen, apotekspersonalet eller sygeplejersken.  </p>
<p>Den anbefalede dosis er 400 mg to gange daglig. Det betyder, at du skal tage to tabletter 
LIVTENCITY 200 mg om morgenen og yderligere to 200 mg tabletter om aftenen. Du kan tage 
lægemidlet med eller uden mad, som en hel tablet eller en knust tablet. </p>
<p>Hvis du har taget for meget LIVTENCITY 
Kontakt straks lægen, hvis du har taget for meget LIVTENCITY. </p>
<p>Hvis du har glemt at tage LIVTENCITY 
Hvis du glemmer en dosis, og der er under 3 timer indtil din næste planlagte dosis, skal du springe den 
glemte dosis over og følge din sædvanlige plan. Tag ikke en dobbeltdosis som erstatning for den 
glemte dosis. </p>
<p>Hvis du holder op med at tage LIVTENCITY 
Selvom du har det bedre, må du ikke holde op med at tage LIVTENCITY uden at tale med lægen. Du 
har den bedste chance for at komme dig over CMV-infektion og/eller -sygdom ved at tage 
LIVTENCITY som anbefalet. </p>
<p>Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
Fortæl lægen, apotekspersonalet eller sygeplejersken, hvis du bemærker nogen af følgende 
bivirkninger: </p>
<p>Meget almindelig (kan forekomme hos op til 1 ud af 10 personer): 
 
ændring af, hvordan ting smager 
 
følelse af utilpashed (kvalme) 
 
diarré 
 
føler dig syg (opkastning) 
 
træthed </p>
<p>Almindelig (kan forekomme hos op til 1 ud af 10 personer): 
 
øgede niveauer i blodet af lægemidler, der bruges til at forhindre transplantatafstødning 
 
mavesmerter 
 
appetitløshed 
 
hovedpine 
 
vægttab </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store livtencity"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store livtencity"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter EXP. Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 30 °C. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>LIVTENCITY indeholder:</p>
<ul>
<li>Aktivt stof: maribavir. Hver filmovertrukken tablet indeholder 200 mg maribavir </li>
<li>
<p>Øvrige indholdsstoffer (hjælpestoffer):</p>
</li>
<li>
<p>Tabletkerne:</p>
</li>
<li>
<p>Mikrokrystallinsk cellulose (E460(i)), natriumstivelsesglycolat (se punkt 2), magnesiumstearat 
(E470b)  </p>
</li>
<li>
<p>Filmovertræk:</p>
</li>
<li>
<p>Polyvinylalkohol (E1203), Macrogol (dvs. polyethylenglycol) (E1521), titandioxid (E171), talcum 
(E553b), Brilliant Blue FCF aluminum lake (EU) (E133) </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser 
LIVTENCITY 200 mg filmovertrukne tabletter er blå, ovale og konvekse tabletter, der er præget med 
"SHP" på den ene side og "620" på den anden side. </p>
<p>Tabletterne er pakket i beholdere (af HDPE) med børnesikret låg, der indeholder enten 28, 56 eller (2 beholdere med 56) filmovertrukne tabletter. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Takeda Pharmaceuticals International AG Ireland Branch 
Block 2 Miesian Plaza 
50-58 Baggot Street Lower 
Dublin 2 
D02 HWIrland </p>
<p>Fremstiller 
Takeda Ireland Limited 
Bray Business Park 
Kilruddery 
Co. Wicklow 
Irland </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Takeda Belgium NV 
Tél/Tel: +32 2 464 06 11<br />
medinfoEMEA@takeda.com </p>
<p>Lietuva 
Takeda, UAB 
Tel: +370 521 09 medinfoEMEA@takeda.com </p>
<p>България 
Такеда България ЕООД 
Тел.: +359 2 958 27 medinfoEMEA@takeda.com  </p>
<p>Luxembourg/Luxemburg 
Takeda Belgium NV 
Tél/Tel: +32 2 464 06 medinfoEMEA@takeda.com  </p>
<p>Česká republika 
Takeda Pharmaceuticals Czech Republic s.r.o. 
Tel: + 420 234 722 722<br />
medinfoEMEA@takeda.com </p>
<p>Magyarország 
Takeda Pharma Kft. 
Tel.: +36 1 270 7medinfoEMEA@takeda.com </p>
<p>Danmark 
Takeda Pharma A/S 
Tlf: +45 46 77 10 medinfoEMEA@takeda.com </p>
<p>Malta 
Τakeda HELLAS S.A. 
Tel: +30 210 6387medinfoEMEA@takeda.com </p>
<p>Deutschland 
Takeda GmbH 
Tel: +49 (0)800 825 3medinfoEMEA@takeda.com </p>
<p>Nederland 
Takeda Nederland B.V. 
Tel: +31 20 203 5medinfoEMEA@takeda.com </p>
<p>Eesti 
Takeda Pharma AS 
Tel: +372 6177 medinfoEMEA@takeda.com </p>
<p>Norge 
Takeda AS 
Tlf: +47 800 800 medinfoEMEA@takeda.com </p>
<p>Ελλάδα 
Τakeda ΕΛΛΑΣ Α.Ε. 
Tηλ: +30 210 6387medinfoEMEA@takeda.com<br />
Österreich 
Takeda Pharma Ges.m.b.H.<br />
Tel: +43 (0) 800-20 80 50<br />
medinfoEMEA@takeda.com </p>
<p>España 
Takeda Farmacéutica España S.A. 
Tel: +34 917 90 42 medinfoEMEA@takeda.com<br />
Polska 
Takeda Pharma Sp. z o.o. 
Tel.: +48223062medinfoEMEA@takeda.com </p>
<p>France 
Takeda France SAS 
Tél: + 33 1 40 67 33 medinfoEMEA@takeda.com </p>
<p>Portugal 
Takeda Farmacêuticos Portugal, Lda. 
Tel: + 351 21 120 1medinfoEMEA@takeda.com </p>
<p>Hrvatska 
Takeda Pharmaceuticals Croatia d.o.o. 
Tel: +385 1 377 88 medinfoEMEA@takeda.com </p>
<p>România 
Takeda Pharmaceuticals SRL 
Tel: +40 21 335 03 medinfoEMEA@takeda.com 
Ireland 
Takeda Products Ireland Ltd 
Tel: 1800 937 medinfoEMEA@takeda.com </p>
<p>Slovenija 
Takeda Pharmaceuticals farmacevtska družba d.o.o. 
Tel: + 386 (0) 59 082 medinfoEMEA@takeda.com </p>
<p>Ísland 
Vistor hf. 
Sími: +354 535 7medinfoEMEA@takeda.com </p>
<p>Slovenská republika 
Takeda Pharmaceuticals Slovakia s.r.o. 
Tel: +421 (2) 20 602 medinfoEMEA@takeda.com </p>
<p>Italia 
Takeda Italia S.p.A. 
Tel: +39 06 502medinfoEMEA@takeda.com </p>
<p>Suomi/Finland 
Takeda Oy 
Puh/Tel: 0800 774 medinfoEMEA@takeda.com </p>
<p>Κύπρος 
Τakeda ΕΛΛΑΣ Α.Ε. 
Τηλ.: +30 210 6387medinfoEMEA@takeda.com<br />
Sverige 
Takeda Pharma AB 
Tel: 020 795 medinfoEMEA@takeda.com </p>
<p>Latvija 
Takeda Latvia SIA 
Tel: +371 67840medinfoEMEA@takeda.com </p>
<p>United Kingdom (Northern Ireland) 
Takeda UK Ltd 
Tel: +44 (0) 2830 640 medinfoEMEA@takeda.com </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-2c250051417033f9ca5609b812b532b2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for livtencity Package Leaflet for language en"
Description: "ePI document Bundle for livtencity Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-2c250051417033f9ca5609b812b532b2"
* entry[0].resource = composition-en-2c250051417033f9ca5609b812b532b2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp2c250051417033f9ca5609b812b532b2"
* entry[=].resource = mp2c250051417033f9ca5609b812b532b2
                            
                    
Instance: bundlepackageleaflet-da-2c250051417033f9ca5609b812b532b2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for livtencity Package Leaflet for language da"
Description: "ePI document Bundle for livtencity Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-2c250051417033f9ca5609b812b532b2"
* entry[0].resource = composition-da-2c250051417033f9ca5609b812b532b2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp2c250051417033f9ca5609b812b532b2"
* entry[=].resource = mp2c250051417033f9ca5609b812b532b2
                            
                    



Instance: mp2c250051417033f9ca5609b812b532b2
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product livtencity"
Description: "livtencity"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/22/1672/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "livtencity"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 2c250051417033f9ca5609b812b532b2ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "livtencity"

* status = #current
* mode = #working

* title = "List of all ePIs associated with livtencity"

* subject = Reference(mp1ca97300ba5836420ff4607613719f22)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#livtencity "livtencity"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-2c250051417033f9ca5609b812b532b2) // livtencity en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-2c250051417033f9ca5609b812b532b2) // livtencity da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-2c250051417033f9ca5609b812b532b2
InstanceOf: List

* insert 2c250051417033f9ca5609b812b532b2ListRuleset
    